About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, January 3rd, 2013

The QualityStocks
Daily Stock List


Wesdome Gold Mines Ltd. (WDO.TO)

Today we are reporting on Wesdome Gold Mines Ltd. (WDO.TO), here at the QualityStocks Daily Newsletter.

Wesdome Gold Mines Ltd. engages in the exploration, development, and production of mineral resource properties, primarily gold in Canada. The Company is celebrating their 25th year of continuous mining operations in Canada. Currently, Wesdome has three producing gold mines with wholly owned mining and milling complexes located in Wawa, Ontario and Val d'Or, Québec. The Company, based in Toronto, Ontario, lists on the Toronto Stock Exchange

Wesdome Gold Mines is presently focusing on optimizing their assets by way of development and infrastructure investment. On December 30, 2003, the Company completed the purchase of the Kiena Mine property and related infrastructure.

Since the acquisition of the Kiena property, Wesdome initiated a long-term exploration strategy based on: the Mine Area – the compilation and reinterpretation of the immediate potential within the mine area; the East Exploration Drift - the establishment of an eastern exploration drift on the 330 meter level to progressively examine the potential of the Wisik, Martin, Shawkey 22 and Dubuisson Zones, and Property Wide Exploration - progressive compilation of the entire land package to establish priorities for surface drilling.

The Company also has their Eagle River Mine and their Mishi Mine. The Eagle River mine is now in its 17th year of commercial production. In June 2012, it poured its 900,000th ounce of gold. The Mishi-Magnacon complex covers a ten-kilometer strike length of a sheared and altered volcano sedimentary sequence that hosts a number of known gold occurrences.

Yesterday, Wesdome Gold Mines reported that the underground exploration drilling results at the Kiena Mine continue to provide encouraging results. An underground exploration drilling program of the S-50 Zone at the Kiena Mine began during September 2010. Drill results demonstrate a continuity of the S-50 (South Zone) mineralized system toward the southeast and at depth with a series of steeply dipping sub-parallel zones intersected by several of the drill holes.

Highlights include 6.01 gAu/tonne over 10.0 m (core length), 8.78 m (true width) in hole U-5454;  5.08 gAu/tonne over 6.4 m (core length), 1.93 m (true width) in hole U-5667;  6.61 gAu/tonne over 11.8 m (core length), 2.20 m (true width) in hole U-5402;  3.72 gAu/tonne over 11.0 m (core length), 6.75 m (true width) in hole U-5161, and 5.28 gAu/tonne over 2.8 m (core length),  1.53 m (true width) in hole U-5529.

Highlights also include 4.89 gAu/tonne over 6.1 m (core length),  4.45 m (true width) in hole U-4998; 21.07 gAu/tonne over 7.5 m (core length), 7.30 m (true width) in hole U-5454; 10.59 gAu/tonne over 5.1 m (core length), 1.53 m (true width) in hole U-5445, and 11.40 gAu/tonne over 3.5 m (core length), 1.07 m (true width) in hole U-5411.

Wesdome Gold Mines Ltd. (WDO.TO), closed Thursday's trading session at $0.85, down 2.30%, on 77,373 volume. The stock's 52-week low/high is $0.75/$2.46.

Genesis Group Holdings, Inc. (GGHO)

TheMicrocapNews reported recently on Genesis Group Holdings, Inc. (GGHO), OTCPicks, OtcWizard did earlier, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Genesis Group Holdings, Inc. is an end-to-end solutions provider of professional services and infrastructure. The Company provides these solutions to the telecommunications industry, major corporations and governmental entities. Founded in 2006, Genesis Group Holdings has their headquarters in Boca Raton, Florida. The Company's shares trade on the OTC Bulletin Board.

The Company's cloud-based and managed services, and engineering, design, construction, project staffing, installation, maintenance and project staffing services support the build-out, maintenance, upgrade and operation of some of the most advanced fiber optic, Ethernet, copper, wireless and satellite networks. Genesis Group Holdings' range of services enables their customers to augment existing services selectively or to outsource entire projects or operational functions.

Currently, the Genesis Group has four subsidiaries: ADEX, Rives-Monteiro, TNS, and Tropical Communications. ADEX is an international service organization that provides E&I services and staffing solutions exclusively to the Telecommunications industry in support of Network Infrastructure Deployments globally. Rives-Monteiro Engineering is a telecommunication company that provides engineering services for the Cable Industry.

TelNet Solutions (TNS, Inc.) is a communications contractor. They specialize in the design, installation and maintenance of structured cabling systems. Tropical Communications is a Florida State Licensed Low Voltage Electrical Contractor.

In November, Genesis Group Holdings announced that they signed a definitive agreement to acquire Integration Partners-NY Corp. (IPC-NY). IPC-NY serves corporate enterprises and service providers. The acquisition of IPC-NY will support Genesis Group Holdings' cloud and managed services, systems integration and applications capabilities.

Last month, Genesis Group announced that Mr. Neal Oristano and Mr. Mark Durfee agreed to serve as Company Directors. Mr. Oristano is in charge of strategic development for Cisco's global service provider market segment. Before joining Cisco, Mr. Oristano was Senior Vice President of the America's for service provider sales with Juniper.

Mr. Durfee has been a private equity investor for 25 years, investing in an extensive portfolio of companies in the manufacturing, education, telecommunications, business and industrial services industries. Mr. Durfee has a B.S. in Finance from the University of Wyoming.

Genesis Group Holdings, Inc. (GGHO), closed Thursday's trading session at $0.016, even for the day, on 947,000 volume with 10 trades. The average volume for the last 60 days is 481,133 and the stock's 52-week low/high is $0.002/$0.041.

Dial Global, Inc. (DIAL)

StreetInsider and SmarTrend Newsletters reported earlier on Dial Global, Inc. (DIAL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Based in New York, New York, Dial Global, Inc. conducts business as an independent, full-service network radio company in the U.S. The Company has their radio networks, which are heard by more than 225 million listeners a week. Dial Global produces more than 200 news, sports, talk, music and entertainment programs, services and digital applications, jingles and imaging. The Company's shares trade on the OTC Market's OTCQB. Dial Global has regional offices across the United States in Atlanta, Chicago, Dallas, Denver, Detroit, Los Angeles, Miami, Nashville, San Francisco, Seattle, and Washington, DC.

Dial Global is America's leading provider and distributor of audio content to more than 8,500 radio stations across the country. They distribute, produce, and/or syndicate programming and services to these radio stations.

The Company also offers audio content from live events, turnkey music formats, and prep services. In addition, Dial Global provides interactive voice response (IVR) phone systems that helps radio stations to answer phones; and facilitates call-ins, contesting, text messaging, and polling.

Furthermore, the Company operates as a sales representative for independent third party providers of audio content. Moreover, Dial Global provides sales networks to advertisers through a spectrum of programming and services. The Company also offers their services through 17 owned and operated Websites.

For advertisers, Dial Global offers sales networks with premier market coverage and powerful targeting through their wide array of programming and station services. This includes personality programming, digital formats, news and information services, prep packages, music libraries and interactive technologies. For content producers, they offer a full-service partnership. Their traffic, research and sales teams are managed by industry veterans.

Recently, Dial Global announced that Launchpad Digital Media would represent the Company's current and future podcast programming. Potential podcast programming from Dial Global includes Dennis Miller, Loveline, Billy Bush, Charles Osgood, Country programming, DG Sports and NBC Sports Radio among others. Launchpad is a division of Norm Pattiz's Courtside Entertainment Group. Currently, Launchpad represents on-demand and streaming podcast programming, which delivers more than 90 million downloads per month.

Dial Global, Inc. (DIAL), closed Thursday's trading session at $0.26, up 6.12%, on 13,700 volume with 4 trades. The average volume for the last 60 days is 21,977 and the stock's 52-week low/high is $0.18/$0.29.

Targeted Medical Pharma, Inc. (TRGM)

We are highlighting Targeted Medical Pharma, Inc. (TRGM), here at the QualityStocks Daily Newsletter.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that lists on the OTC Bulletin Board. The Company develops prescription medical foods for the treatment of chronic diseases. These include pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. In addition, Targeted Medical Pharma provides diagnostic testing and billing and collection services on behalf of dispensing physicians.

Targeted Medical Pharma was originally founded as Targeted Medical Foods in 1999. They became a Limited Liability Company in 2002. The Company began distributing proprietary Rx Medical Foods in the United States in 2001. The Company is based in Los Angeles, California.

The Company manufactures 10 proprietary prescription only medical foods, and 48 convenience packed kits, which pair a medical food and branded or generic pharmaceuticals. These prescription medical foods and therapeutic systems sell to physicians and pharmacies in the United States and the Middle East via Targeted Medical Pharma's subsidiary, Physician's Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

In early December, the Company reported preliminary data indicating that their new amino acid-based oral formulation PERCURA™ reduced symptoms of pain and numbness related to peripheral neuropathy in an open-label pilot study. The medical food PERCURA™ reduced symptoms of numbness in subjects an average of 57 percent, after the first 30 days of treatment. Additionally, the pilot reported an average 56 percent reduction in pain among subjects related to peripheral neuropathy after 30 days of treatment. All subjects were expected to complete the 60-day study by the end of 2012.

Recently, Targeted Medical Pharma announced that members of the Company's executive team are scheduled to present at the sixth annual OneMedForum on January 8, 2013 at 3:40 p.m. PST, to take place at the Sir Francis Drake Hotel in San Francisco, California. Company Management will also conduct one-on-one meetings with investors from January 7-9, 2013, simultaneous with the 31st Annual J.P. Morgan Healthcare Conference.

Targeted Medical Pharma, Inc. (TRGM), closed Thursday's trading session at $2.40, up 20.00%, on 11,700 volume with 19 trades. The average volume for the last 60 days is 2,755 and the stock's 52-week low/high is $1.50/$5.75.

HII Technologies, Inc. (HIIT)

FeedBlitz, PennyToBuck, CRWEWallStreet, CRWEFinance, StockHotTips, BestOtc, CRWEPicks, and PennyOmega reported earlier on HII Technologies, Inc. (HIIT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, HII Technologies, Inc. is an oilfield services company with operations in Texas and Oklahoma. They focus on commercializing technologies in power and water management used by exploration and production companies in the U.S. HII Technologies has their corporate headquarters in Houston, Texas.

The Company changed their name in August 2011 to HII Technologies, Inc. in connection with selling the name and assets of their oilfield valve technology they had previously developed. HII has focused on power and water management solutions in the oilfield for E&P customers via acquisitions and potential organic growth since the sale of their oilfield product line.

The Company's total water management services subsidiary, Apache Energy Services, LLC, does business as AES Water Solutions. HII Technologies' mobile oilfield power subsidiary, KMHVC, does business as South Texas Power (STP).  The STP division focuses on providing onsite portable power to exploration and production (E&P) companies where power grid connectivity is lacking. 

HII's Plan of Operation for the coming months includes continuing to review drilling and production products and services technologies developed by inventors, design and operating companies. The Company's plan is to in-license, acquire, or develop internally, products or services that can be of strategic value to the Company's current focus of water transfer and in-field mobile power generation. Their intention is to use their relationships with larger energy services companies, end user customers and their supply chain experience to grow AES and later South Texas Power.

This past November, HII Technologies announced a major purchase of water transfer related equipment for use in their AES oilfield frac-related water transfer services division. On November 8, 2012, they purchased more than a half million dollars of assets. These included 10-plus miles of above ground high-volume water transfer pipe, numerous trucks, trailers, manifolds, road crossings, fittings and related equipment. These assets underwent immediate deployment by AES to service expanding relationships with existing and new customers in shale, limestone and other tight oil unconventional reservoir areas.

HII Technologies, Inc. (HIIT), closed Thursday's trading session at $0.102, down 2.86%, on 38,000 volume with 3 trades. The average volume for the last 60 days is 50,500 and the stock's 52-week low/high is $0.015/$0.105.

GeoBio Energy, Inc. (GBOE)

HotStockCafe, Nickel Stock Pick, Penny PayDay, New Stock Idea, PennyRally, and Blue Chip Maker reported previously on GeoBio Energy, Inc. (GBOE), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in the State of Washington, GeoBio Energy, Inc.'s corporate business model emphasizes the development, acquisition and operation of existing companies in the oil and gas services and energy related products industry. The Company's subsidiary, El Gas North America, LLC, has an exclusive license to sell Czech Republic based El Gas NA s.r.o.'s natural gas electronic volume corrector (EVC) and electronic data recorder (EDR) products in the U.S., Canada, Mexico and the Caribbean. These products provide for the efficient monitoring and delivery of natural gas to consumers. GeoBio Energy's shares trade on the OTC Bulletin Board.

GeoBio Energy is working to become a dominant player in the oil and natural gas services field. Their intention is to add key strategic acquisitions that will add geographic reach and new capabilities. GeoBio is interested in companies with the following services and core products: fluids and solids hauling and disposal, tank pumps and equipment rentals, well cleaning, and nitrogen injection.

The Company is targeting for acquisition entities that have an aggressive skilled management team, a history of profitability, a strong local identity, a good relationship with customers and suppliers, a strategic service area, and a minimum of one unique product offering. GeoBio Energy's intention is that these individual companies remain locally managed.

In early December 2012, GeoBio Energy announced that their wholly owned subsidiary, El Gas North America, made available for sale to utilities and related consumers the maxiElcor.  The maxiElcor is the only Electronic Gas Volume Corrector (cash register for the gas utility) available that can stand-alone in the field for up to five years (no maintenance is required) and manage and report remotely, specific activity related to the transfer and delivery of natural gas. 

The use of the maxiElcor is for commercial, industrial, pipeline and production applications. It corrects for actual gas flow, temperature, pressure correction and supercompressability.

GeoBio Energy, Inc. (GBOE), closed Thursday's trading session at $0.0279, up 46.84%, on 18,653 volume with 5 trades. The average volume for the last 60 days is 25,408 and the stock's 52-week low/high is $0.005/$0.05.

Scio Diamond Technology Corp. (SCIO)

FeedBlitz reported earlier on Scio Diamond Technology Corp. (SCIO), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Scio Diamond Technology Corp. focuses on developing and producing lab-grown or cultured diamonds. The Company employs a patent-protected chemical vapor deposition process to produce high-quality, single-crystal diamonds in a controlled laboratory setting. Scio produces diamonds for industrial, gemstone, medical as well as semiconductor applications. The Company lists on the OTC Bulletin Board. Scio Diamond Technology has their headquarters in Greenville, South Carolina.

The Company's cultivated diamonds have chemical, physical and optical properties identical to mined diamonds. Scio's manufacturing process enables the Company to produce high quality, high-purity, single-crystal colorless, near colorless and fancy colored diamonds. Their technology offers the flexibility to produce lab-grown diamonds in size, color and quality combinations that are very rare in nature.

The basis of the core technology is on a chemical vapor deposition (CVD) diamond growth system.  As of December 2011, Scio Diamond had thirteen patents (10 US [9 issued; 1 claim allowed]; 1 Australia; 2 China) related to their technology with approximately 40 domestic and foreign patents pending.

In November 2012, the Company announced that they exceeded 6,500 carats of diamond growth since the start of production. Scio has successfully grown diamond using 52 seeds in a single run. Mr. Joseph Lancia, Scio's President and CEO, said in November, "In October, we announced that we had increased our crystals per growth run from 12 to 25. We are now averaging over 40 crystals per run and have recently made our first two successful runs at 52 crystals. No one in the world, to our knowledge, has ever accomplished this before."

In December, Scio Diamond Technology announced that their Board of Directors appointed Mr. Steve Kelley as Chief Executive Officer, effective December 5, 2012. Mr. Kelley has close to 20 years of leadership experience in technology businesses, most recently as Chief Operating Officer and Executive Vice President of Cree, Inc., a worldwide leader in LED, silicon carbide and gallium nit ride material technologies.

Scio Diamond Technology Corp. (SCIO), closed Thursday's trading session at $1.28, up 11.30%, on 42,100 volume with 7 trades. The average volume for the last 60 days is 18,552 and the stock's 52-week low/high is $0.711/$4.18.

Casablanca Mining Ltd. (CUAU)

BUYINS.NET, Penny Stocks VIP, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, CRWEWallStreet, CRWEFinance, StockHotTips, CRWEPicks, PennyToBuck, DrStockPick, and PennyOmega reported on Casablanca Mining Ltd. (CUAU), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Casablanca Mining Ltd. engages in the acquisition, exploration, development, and operation of precious metal properties in South America. The Company accomplishes this via their wholly owned subsidiary Santa Teresa Minerals, S.A. Their gold and copper mining operations are based near Santiago, Chile. Casablanca Mining lists on the OTC Market's OTCQX U.S. The Company has their headquarters in Santee, California. They also have an office in Santiago, Chile.

Currently, Casablanca Mining's Santa Teresa Minerals has, directly and indirectly through various equity interests, mining rights in 80 different mining and mineral exploration properties. These include gold, copper and copper sulfate. Santa Teresa Minerals has mining rights in exploration projects, "Free Gold", the "Casuto Project," consisting of Los Azules 1-3, Tauro 1-6, Los Chipi 1-22, and the "New Gold Project," consisting of Los Pinos 1-30 and Teresita 1-20. The Company also has a 50/50 revenue-share at the now operational "Las Dichas" alluvial gold mine.
In addition, Santa Teresa Minerals owns an equity position of Bluestone S.A., a copper sulfate production project that owns the Anica Copper Mines. Santa Teresa Minerals additionally owns a 60 percent equity position in a company with the rights to an innovative mining technology that extracts gold, silver, and copper from raw mining materials using a proprietary and patented electrolysis method of electromining.

Last month, Casablanca Mining announced that they made significant advances in the construction of their Los Pinos hard rock gold project in Rancagua, Chile. They completed road improvements, a platform terrace, and tunnel entrances. The Company has opened two separate tunnels (Level 2 and Level 3) that enter the mine. The mine covers an area of 400 hectares and corresponds to a first vein that shows significant potential for gold.

The mining property includes 300 hectares called, "Los Pinos 1-30" and 100 hectares called "Teresita 1-20." The properties are in the Valley of Cachapoal, on the plateau that lies to the West of the village of Coltauco, 55 kilometers from the city of Rancagua, approximately 150 kilometers from Santiago.

Casablanca Mining Ltd. (CUAU), closed Thursday's trading session at $0.29, up 16.47%, on 147,703 volume with 32 trades. The average volume for the last 60 days is 281,073 and the stock's 52-week low/high is $0.051/$5.00.


The QualityStocks
Company Corner


Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.033, up 13.79%, on 2,602,512 volume with 91 trades. The stock’s average daily volume over the past 60 days is 1,949,737, and its 52-week low/high is $0.0275/$0.179.

Advaxis, Inc. reported today on the appointment of 15-year veteran biopharmaceutical industry executive, legal, and regulatory professional, Daniel J. O’Connor, to Senior Vice President, Chief Legal, and Business Development Officer. O’Connor brings a rich experiential history working in the trenches at top firms like ImClone Systems, PharmaNet, and Bracco Diagnostics and will serve the interests of next-gen immunotherapy developer Advaxis superbly well, having also been a criminal prosecutor in the tough New Jersey court system, as well as serving as a U.S. Marine Corps Captain in the Persian Gulf (1990).

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer

Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority

Advaxis Presents at NYC MedTech Program

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.203, up 5.45%, on 620,336 volume with 347 trades. The stock’s average daily volume over the past 60 days is 200,560, and its 52-week low/high is $0.17/$0.42.

Cardium Therapeutics, Inc. announced a key distribution agreement today with Academy Medical, LLC to market, sell, and distribute the company's syringe-based, professional-use, pharmaceutically-formulated, and FDA-cleared wound healing product Excellagen (2.6% fibrillar Type I bovine collagen gel) to the U.S. government medical providers, including the nation's largest integrated healthcare system, the Veterans Administration ($50B plus budget). Excellagen is ideal for follow up treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds following standard debridement procedures.

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

Cardium Announces Sales and Distribution Agreement With Academy Medical to Promote Excellagen Clinical Adoption by U.S. Government Medical Providers

Cardium Announces Patent Award For Rights To Gene Therapy for Coronary Heart Disease, Resolves Long-standing IP Competition

Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $9.15, up 3.98%, on 37,508 volume with 84 trades. The stock’s average daily volume over the past 60 days is 31,306, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. announced today that the company's CEO, Noreen McGurrin Griffin and CMO, Dr. Ronald Herberman, will be presenting on TNI BioTech's business activities this January 7th to the 9th at this year's Annual OneMedForum, hosted at the Sir Frances Drake Hotel, in San Francisco, CA. The company will present venue goers with a thorough look at the exciting progress made by TNIB in developing biotech solutions to fatal diseases through the safe activation of the body's own immune system, starting at 11:20 am PST (2:20 EST), on Wednesday, January 9.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech to Present at 6th Annual OneMedForum San Francisco 2013

Umbrella Research Initiates Coverage on TNI BioTech

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.19, off by 5.00%, on 49,811 volume with 17 trades. The stock’s average daily volume over the past 60 days is 133,839, and its 52-week low/high is $0.161/$0.68.

International Stem Cell Corp. announced today that the company's Exec. VP, Dr. Simon Craw, will offer a presentation on the company's revolutionary work in therapeutic applications of human parthenogenetic stem cells at the Biotech Showcase™ 2013 this coming Monday, January 7th at 9:30 a.m. PST, in the Parc 55 Wyndham Union Square Hotel, San Francisco, CA. Parties interested in attending the conference can contact the event organizers on the Conference Website or through Mark McPartland of the MZ Group via Email markmcp@mzgroup.us or Phone 212-301-7130 to arrange a meeting with management at the conference.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th

Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns

German Court Decision May Strengthen International Stem Cell Corporation's Position in European Market

Daniel J. O’Connor Appointed to Advaxis, Inc. (ADXS) Senior Vice President, Chief Legal and Business Development Officer Position

Advaxis, a biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O’Connor to the position of Senior Vice President, Chief Legal and Business Development Officer. Mr. O’Connor joins the management team with fifteen years of executive, legal, and regulatory experience in the biopharmaceutical industry.

“We are delighted to welcome Dan O’Connor to Advaxis,” stated Thomas Moore, Advaxis’ Chairman and Chief Executive Officer. “Now that our clinical development has reached an advanced stage, his success as a general counsel and in leading business development and licensing negotiations is a timely addition to our management team. We are very fortunate to attract a highly experienced professional of this caliber. It is a significant endorsement of Advaxis’ immunotherapy technology and our potential to unlock unrealized enterprise value.”

“I believe that Advaxis’ future holds tremendous potential,” commented Mr. O’Connor. “I look forward to continuing the company’s culture of decisiveness and efficient execution. We will aggressively advance ADXS-HPV and our other pipeline product candidates, while building commercial alliances to both accelerate product development and generate shareholder value.”

Joining ImClone in 2003, Mr. O’Connor supported the clinical development, launch, and commercialization of ERBITUX(R). As ImClone’s senior vice president, general counsel, and secretary, he played a key role in resolving numerous issues facing ImClone, including extensive licensing negotiations, in advance of the company being sold to Eli Lilly (NYSE: LLY) in 2008.

Prior to ImClone, Mr. O’Connor was PharmaNet’s general counsel and instrumental in building the company from a start-up contract research organization to an established world leader in clinical research. Mr. O’Connor was also a criminal prosecutor in New Jersey and gained leadership experience as a Captain in the U.S. Marines, serving in the Persian Gulf in 1990. Most recently, while at Bracco Diagnostics, Mr. O’Connor was the company’s vice president and general counsel.

For more information on Advaxis and its fifteen distinct constructs, all of which are involved in strategic collaborations with recognized centers of excellence, visit www.Advaxis.com

Cardium Therapeutics, Inc. (CXM) to Increase Excellagen Clinical Adoption by U.S. Government Medical Providers via New Distribution Agreement

Today before the opening bell, Cardium Therapeutics announced it has entered a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals.

An FDA-cleared gel, Excellagen is used to support advanced wound care in a broad range of dermal wounds. Academy Medical’s will initially focus on providing education and training on the use of Excellagen in the treatment of traumatic wounds, non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery, while supporting distribution within its growing customer base of over 35 VA and military hospitals within the U.S.

The VA operates the nation’s largest integrated healthcare system. With a healthcare budget of over $50 billion, VA has estimated more than 6.0 million patients were provided with care during over 900,000 inpatient hospital admissions and nearly 80 million outpatient visits during 2012. VA’s healthcare network includes 152 major medical centers and more than 800 community-based outpatient clinics.

“As the U.S. healthcare market continues to expand due to the aging population and with the implementation of the Affordable Care Act, simpler-use and more cost-effective medical products like Excellagen have an opportunity to expand and grow within outcomes-oriented healthcare settings,” commented Christopher J. Reinhard, Chairman and CEO of Cardium. “Our agreement with Academy Medical expands Cardium’s tactical access and distribution capabilities for Excellagen as we advance forward with our planned U.S. strategic partnering activities. We are in discussions with potential strategic partners to establish representation, marketing and sales, or co-promotional arrangements along four U.S. vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government medical service providers; and (4) dermatology.”

There have been important, positive findings reported by physicians using Excellagen. To review case studies, visit www.excellagen.com/surgical-wounds.html.

For more information on Cardium Therapeutics, visit www.CardiumTHX.com

TNI BioTech, Inc. (TNIB) Scheduled to Present at 6th Annual OneMedForum Conference

TNI BioTech, a biotech company utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, today announced that CEO Noreen McGurrin Griffin and CMO Dr. Ronald Herberman will be speaking at the 6th Annual OneMedForum taking place in San Francisco, CA, on January 7-9, 2013.

Ms. Griffin and Dr. Herberman will provide an update on the company’s business activities for 2012 as well as plans for 2013. TNI BioTech’s presentation is scheduled for Wednesday, January 9, 2013, at 11:20 am PST.

For more information on TNI BioTech, visit www.TNIBioTech.com

International Stem Cell Corp. (ISCO) Scheduled to Present at the Biotech Showcase 2013 Conference

International Stem Cell Corp., a biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, today announced that Executive Vice President, Dr. Simon Craw, will be presenting at the Biotech Showcase™ 2013 conference early next week. The event is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.

Presentation Details

Date: Monday, January 7, 2013
Time: 9:30 pm PST
Location: Parc 55 Wyndham Union Square Hotel, San Francisco, CA
Room: Room Mission II – Track C

Those who wish to attend the conference or arrange a meeting with ISCO’s management team should contact the conference organizers. To register for the event, visit the conference Web site at www.ebdgroup.com/bts/registration/index.php.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event. For more information, please visit the conference Web site at www.ebdgroup.com/bts/index.php.

The investor presentation delivered at the Biotech Showcase conference will be available on the investor relations section of ISCO’s Web site at www.internationalstemcell.com.


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Investor News Source

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251